# MSP Recovery, Inc.: financial statements, quarterly

MSPR · CIK 1802450 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mspr.md) · [Financials](/companies/mspr/financials.md) · [Filings](/companies/mspr/filings.md) · [Insiders](/companies/mspr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mspr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $m | [(136) d](/filings/0000950170-24-044197.md) | [(141)](/filings/0000950170-24-060463.md) | [(141)](/filings/0000950170-24-097154.md) | [(137)](/filings/0000950170-24-127034.md) | [(142) d](/filings/0000950170-25-054434.md) | [(130)](/filings/0000950170-25-072820.md) | [(135)](/filings/0001802450-25-000017.md) | [(130)](/filings/0001193125-25-288180.md) | [(879) d](/filings/0000950170-25-054434.md) | [(127)](/filings/0000950170-25-072820.md) | [(125)](/filings/0001802450-25-000017.md) | [(124)](/filings/0001193125-25-288180.md) |
| Interest expense | $m | [40.1 d](/filings/0000950170-24-044197.md) | [42.4](/filings/0000950170-24-060463.md) | [73.6](/filings/0000950170-24-097154.md) | [88.3](/filings/0000950170-24-127034.md) | [84.9 d](/filings/0000950170-25-054434.md) | [98.0](/filings/0000950170-25-072820.md) | [102](/filings/0001802450-25-000017.md) | [107](/filings/0001193125-25-288180.md) | [113 d](/filings/0000950170-25-054434.md) | [119](/filings/0000950170-25-072820.md) | [125](/filings/0001802450-25-000017.md) | [130](/filings/0001193125-25-288180.md) |
| Income tax | $m | [0.3 d](/filings/0000950170-24-044197.md) | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-25-288180.md) | [0.0 d](/filings/0000950170-25-054434.md) | not reported | not reported | [0.0](/filings/0001193125-25-288180.md) |
| Net income | $m | [(3.5) d](/filings/0000950170-24-044197.md) | [(4.9)](/filings/0000950170-24-060463.md) | [(8.2)](/filings/0000950170-24-097154.md) | [(19.8)](/filings/0000950170-24-127034.md) | [(23.5) d](/filings/0000950170-25-054434.md) | [(18.9)](/filings/0000950170-25-072820.md) | [(25.1)](/filings/0001802450-25-000017.md) | [(29.8)](/filings/0001193125-25-288180.md) | [(287) d](/filings/0000950170-25-054434.md) | [(122)](/filings/0000950170-25-072820.md) | [(143)](/filings/0001802450-25-000017.md) | [(168)](/filings/0001193125-25-288180.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported

## Balance sheet

| Line item | Unit | FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.7](/filings/0000950170-24-044197.md) | [21.6](/filings/0000950170-23-043270.md) | [6.4](/filings/0000950170-23-045529.md) | [6.7](/filings/0000950170-23-063845.md) | [11.6](/filings/0000950170-25-054434.md) | [7.1](/filings/0000950170-24-097154.md) | [7.1](/filings/0000950170-24-097154.md) | [4.7](/filings/0000950170-24-127034.md) | [12.3](/filings/0001193125-25-288180.md) | [9.1](/filings/0000950170-25-072820.md) | [4.0](/filings/0001802450-25-000017.md) | [1.8](/filings/0001193125-25-288180.md) |
| Current assets | $m | [51.4](/filings/0000950170-24-044197.md) | [50.2](/filings/0000950170-23-043270.md) | [31.2](/filings/0000950170-23-045529.md) | [23.1](/filings/0000950170-23-063845.md) | [21.9](/filings/0000950170-25-054434.md) | [19.2](/filings/0000950170-24-060463.md) | [13.1](/filings/0000950170-24-097154.md) | [10.8](/filings/0000950170-24-127034.md) | [15.5](/filings/0001193125-25-288180.md) | [12.7](/filings/0000950170-25-072820.md) | [7.7](/filings/0001802450-25-000017.md) | [4.7](/filings/0001193125-25-288180.md) |
| Total assets | $m | [3,418](/filings/0000950170-24-044197.md) | [3,550](/filings/0000950170-23-043270.md) | [3,411](/filings/0000950170-23-045529.md) | [3,282](/filings/0000950170-23-063845.md) | [3,160](/filings/0000950170-25-054434.md) | [3,036](/filings/0000950170-24-060463.md) | [2,909](/filings/0000950170-24-097154.md) | [2,788](/filings/0000950170-24-127034.md) | [1,919](/filings/0001193125-25-288180.md) | [1,798](/filings/0000950170-25-072820.md) | [1,674](/filings/0001802450-25-000017.md) | [1,552](/filings/0001193125-25-288180.md) |
| Current liabilities | $m | [116](/filings/0000950170-24-044197.md) | [109](/filings/0000950170-23-043270.md) | [107](/filings/0000950170-23-045529.md) | [42.5](/filings/0000950170-23-063845.md) | [46.5](/filings/0000950170-25-054434.md) | [82.8](/filings/0000950170-24-060463.md) | [90.5](/filings/0000950170-24-097154.md) | [1,206](/filings/0000950170-24-127034.md) | [1,265](/filings/0001193125-25-288180.md) | [522](/filings/0000950170-25-072820.md) | [563](/filings/0001802450-25-000017.md) | [712](/filings/0001193125-25-288180.md) |
| Total liabilities | $m | [1,231](/filings/0000950170-24-044197.md) | [1,536](/filings/0000950170-23-043270.md) | [1,607](/filings/0000950170-23-045529.md) | [1,638](/filings/0000950170-23-063845.md) | [1,741](/filings/0000950170-25-054434.md) | [1,793](/filings/0000950170-24-060463.md) | [1,875](/filings/0000950170-24-097154.md) | [1,941](/filings/0000950170-24-127034.md) | [2,047](/filings/0001193125-25-288180.md) | [2,160](/filings/0000950170-25-072820.md) | [2,278](/filings/0001802450-25-000017.md) | [2,397](/filings/0001193125-25-288180.md) |
| Shareholders' equity | $m | [108](/filings/0000950170-24-044197.md) | [120](/filings/0000950170-23-043270.md) | [134](/filings/0000950170-23-045529.md) | [285](/filings/0000950170-23-063845.md) | [272](/filings/0000950170-25-054434.md) | [263](/filings/0000950170-24-060463.md) | [261](/filings/0000950170-24-097154.md) | [300](/filings/0000950170-24-127034.md) | [101](/filings/0001193125-25-288180.md) | [(60.8)](/filings/0000950170-25-072820.md) | [(207)](/filings/0001802450-25-000017.md) | [(564)](/filings/0001193125-25-288180.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.9) d](/filings/0000950170-24-044197.md) | [(10.0)](/filings/0000950170-24-060463.md) | [(14.6) d](/filings/0000950170-24-097154.md) | [(6.9) d](/filings/0000950170-24-127034.md) | [(8.5) d](/filings/0000950170-25-054434.md) | [(2.1)](/filings/0000950170-25-072820.md) | [(9.0) d](/filings/0001802450-25-000017.md) | [(6.7) d](/filings/0001193125-25-288180.md) | [1.7 d](/filings/0000950170-25-054434.md) | [(7.2)](/filings/0000950170-25-072820.md) | [(8.5) d](/filings/0001802450-25-000017.md) | [(3.4) d](/filings/0001193125-25-288180.md) |
| Capital expenditure | $m | [1.1 d](/filings/0000950170-24-044197.md) | [0.7](/filings/0000950170-24-060463.md) | [0.7 d](/filings/0000950170-24-097154.md) | [0.3 d](/filings/0000950170-24-127034.md) | [0.1 d](/filings/0000950170-25-054434.md) | [0.0](/filings/0000950170-25-072820.md) | [0.1 d](/filings/0001802450-25-000017.md) | [0.0 d](/filings/0001193125-25-288180.md) | [0.4 d](/filings/0000950170-25-054434.md) | [0.2](/filings/0000950170-25-072820.md) | [0.0 d](/filings/0001802450-25-000017.md) | [0.0 d](/filings/0001193125-25-288180.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Shares outstanding: 66,142,649 at 2022-07-31, from the cover of the [10-Q filed 2022-08-12](/filings/0000950170-22-017118.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.